Literature DB >> 19278485

Pharmacological attempts to reduce posterior capsule opacification after cataract surgery--a review.

Thomas D Walker1.   

Abstract

Reduction of posterior capsule opacification (PCO) after cataract surgery has been achieved since the general acceptance of posterior chamber intraocular lens implantation 30 years ago. Attention to surgical technique on the one hand and changes in lens design and materials on the other have synergistically reduced the incidence of PCO to less than 5% at 5 years. But lens epithelial cells still proliferate and pharmacological prevention has been largely unsuccessful so far. Any agent must be toxic to these lens epithelial cells without being toxic to the corneal endothelium. This review looks at many substances that have been tried and a few that have been partly successful without yet entering clinical practice. Possibilities for future clinical research are canvassed.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19278485     DOI: 10.1111/j.1442-9071.2009.01921.x

Source DB:  PubMed          Journal:  Clin Exp Ophthalmol        ISSN: 1442-6404            Impact factor:   4.207


  10 in total

1.  Sustained-release celecoxib from incubated acrylic intraocular lenses suppresses lens epithelial cell growth in an ex vivo model of posterior capsule opacity.

Authors:  Jennifer L Davis; Na Young Yi; Jacklyn H Salmon; Anna N Charlton; Carmen M H Colitz; Brian C Gilger
Journal:  J Ocul Pharmacol Ther       Date:  2012-02-28       Impact factor: 2.671

2.  [Alkylphosphocholines inhibit lens epithelial cell proliferation and attachment].

Authors:  R Liegl; M Kernt; K Obholzer; A Wolf; R Schumann; C Haritoglou; A Kampik; K H Eibl-Lindner
Journal:  Ophthalmologe       Date:  2010-10       Impact factor: 1.059

3.  Cataract surgeon viewpoints on the need for novel preventative anti-inflammatory and anti-posterior capsular opacification therapies.

Authors:  Mahbubul H Shihan; Samuel G Novo; Melinda K Duncan
Journal:  Curr Med Res Opin       Date:  2019-08-28       Impact factor: 2.580

4.  Establishment of a Clinically Relevant Ex Vivo Mock Cataract Surgery Model for Investigating Epithelial Wound Repair in a Native Microenvironment.

Authors:  Janice L Walker; Brigid M Bleaken; Iris M Wolff; A Sue Menko
Journal:  J Vis Exp       Date:  2015-06-05       Impact factor: 1.355

5.  EGFR inhibitor Gefitinib attenuates posterior capsule opacification in vitro and in the ex vivo human capsular bag model.

Authors:  Christian Wertheimer; Jakob Siedlecki; Daniel Kook; Wolfgang J Mayer; Armin Wolf; Annemarie Klingenstein; Anselm Kampik; Kirsten Eibl-Lindner
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2014-12-05       Impact factor: 3.117

Review 6.  Intraocular lens optic edge design for the prevention of posterior capsule opacification after cataract surgery.

Authors:  Sophie Maedel; Jennifer R Evans; Annette Harrer-Seely; Oliver Findl
Journal:  Cochrane Database Syst Rev       Date:  2021-08-16

7.  EGF receptor inhibitor erlotinib as a potential pharmacological prophylaxis for posterior capsule opacification.

Authors:  C Wertheimer; R Liegl; M Kernt; W Mayer; D Docheva; A Kampik; K H Eibl-Lindner
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2013-01-18       Impact factor: 3.117

8.  Modulation of matrix metalloproteinase activity by EDTA prevents posterior capsular opacification.

Authors:  Sarbani Hazra; Rajdeep Guha; Geram Jongkey; Himangshu Palui; Akhilesh Mishra; Geeta K Vemuganti; Samar K Basak; Tapan Kumar Mandal; Aditya Konar
Journal:  Mol Vis       Date:  2012-06-22       Impact factor: 2.367

9.  In vitro growth of lens epithelial cells from cataract patients - association with possible risk factors for posterior capsule opacification.

Authors:  Karin Sundelin; Anne Petersen; Yalda Soltanpour; Madeleine Zetterberg
Journal:  Open Ophthalmol J       Date:  2014-05-30

10.  Novel Technique of Pneumatic Posterior Capsulorhexis for Treatment and Prevention of Posterior Capsular Opacification.

Authors:  Ahmed M Eid; Shaaban Abd-Elhamid Mehany Elwan; Ahmed M Sabry; Hossam M Moharram; Ashraf M Bakhsh
Journal:  J Ophthalmol       Date:  2019-12-21       Impact factor: 1.909

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.